Health
AstraZeneca’s Farxiga prolongs survival in chronic kidney disease trial – Clinical Trials Arena
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease…
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD).
The trial data showed that Farxiga helped reduce the composite of worsening of kidney function or risk of cardiovascular (CV) or renal death.
Farxiga is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used for treating patients with insufficiently controlled type-2 diabetes (T2D).
The international, multi-centre, randomised and…
-
Noosa News21 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General19 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
General23 hours agoMan dies at shopping centre car park at Charlestown following reports of assault
-
Noosa News23 hours agoWomen’s Softball World Cup 2027 Redcliffe Brisbane